A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers (NCT03448042)
A Phase Ia/Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Runimotamab Administered Intravenously as a Single Agent and in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in combination with Trastuzumab in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.
Who can join: Review the eligibility criteria below.
Location: Yale University — New Haven, Connecticut
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- Yale University — New Haven, Connecticut
- Washington University — Saint Louis, Michigan
- Memorial Sloan Kettering Cancer Center — New York, New York
- SCRI Oncology Partners — Nashville, Tennessee
- MD Anderson Cancer Center — Houston, Texas
- Peter MacCallum Cancer Centre — Melbourne, Victoria
- Grand Hopital de Charleroi asbl — Charleroi,
- Princess Margaret Hospital — Toronto, Ontario
- Rigshospitalet-Blegdamsvej 9 — Copenhagen,
- EDOG - Institut Bergonie - PPDS — Bordeaux, Gironde
- Centre Léon Bérard — Lyon, Rhône
- Gustave Roussy — Villejuif, Val-de-Marne
- Institut Claudius Regaud — Toulouse,
- ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda — Milan, Lombardy
- Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis — Amsterdam,
- National Cancer Centre — Singapore,
- Asan Medical Center — Seoul,
- Seoul National University Hospital — Seoul,
- Hospital Universitario Quironsalud Madrid — Pozuelo de Alarcón, Madrid
- Hospital Universitari Vall d'Hebron — Barcelona,
- START MADRID_Hospital Universiario Fundacion Jimenez Diaz — Madrid,
- START MADRID_Hospital Universitario HM Sanchinarro - CIOCC - EDOS — Madrid,
- Hospital Clinico Universitario de Valencia — Valencia,
- China Medical University Hospital — Taichung,
- National Taiwan University Hospital — Taipei,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumors
- Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
- Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
- A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
- Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
- Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona
Explore by condition: All Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.